Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03765762 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease
A Phase 2 study, sponsored by Alkahest.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT03765762: Completed Phase 2 study, sponsored by Alkahest.
NCT03765762 is a Phase 2 study that has completed, run by Alkahest. The registered enrollment target is 26 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03765762, a Phase 2 study, has completed, sponsored by Alkahest.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, and potential cognitive benefit of the experimental treatment GRF6019 in subjects with severe Alzheimer's disease.
Primary Outcome
Number of Subjects with at Least One Treatment-emergent adverse event by MedDRA preferred term and grouped by MedDRA System Organ Class
Interventions
- OTHER Placebo
- DRUG GRF6019
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2019-01-15 |
| Est. Completion | 2019-12-17 |
| Phase | Phase 2 |
What the finished NCT03765762 record still lists
NCT03765762 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03765762 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03765762 about?
NCT03765762 is a clinical study titled "A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease". This study will evaluate the safety, tolerability, and potential cognitive benefit of the experimental treatment GRF6019 in subjects with severe Alzheimer's disease.
What is the current status of trial NCT03765762?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2019-01-15. Estimated completion is 2019-12-17.
What interventions are being tested in trial NCT03765762?
The interventions under investigation include: Placebo (OTHER), GRF6019 (DRUG).
Who is sponsoring clinical trial NCT03765762?
This trial is sponsored by Alkahest, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03765762's enrollment target sits among peer trials
26 1708th of 2000 higher than 282 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI